共 50 条
- [1] Effect of COMT-inhibitor on Parkinson's disease associated with dementia[J]. MOVEMENT DISORDERS, 2013, 28 : S181 - S181Park, J. W.Lee, K. S.Song, I. U.Kim, J. S.Kim, Y. D.
- [2] Can COMT-inhibitor delay the clinical progression of Parkinson's disease? 2 years follow up pilot study[J]. INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY, 2016, 26 (01) : 38 - 42Song, In-UkKim, Tae-WonYoo, IkdongChung, Yong-AnLee, Kwan-Sung
- [3] Sleep attacks in Parkinson's disease induced by entacapone, a COMT-inhibitor[J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (01) : 121 - 123Santens, P
- [4] The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease[J]. CLINICAL NEUROPHARMACOLOGY, 2000, 23 (03) : 143 - 148Chong, DJSuchowersky, OSzumlanski, CWeinshilboum, RMBrant, RCampbell, NRC
- [6] Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1615): : 3 - 5不详
- [7] Comparison of the pharmacokinetics between a COMT-inhibitor and levodopa[J]. MOVEMENT DISORDERS, 2011, 26 : S283 - S283Nagai, M.Kubo, M.Kyaw, W. T.Nishikawa, N.Nomoto, M.
- [8] COMT-Inhibitor, What to do beyond the Honeymoon?[J]. NERVENHEILKUNDE, 2011, 30 (12) : 1020 - 1020Jaeger-Becker, Dagmar
- [9] Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor[J]. NEUROLOGICAL SCIENCES, 2003, 24 (03) : 217 - 218Stocchi, FVacca, LGrassini, PBattaglia, GOnofrj, MValente, MRuggieri, S
- [10] Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease[J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (09) : 1159 - 1166St Onge, ErinVanderhoof, MichelleMiller, Shannon